GlobeNewswire: BioNovelus Inc. Contains the last 10 of 34 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T09:52:33ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2018/08/08/1548784/0/en/BioNovelus-Announces-Marvin-R-Clark-Leaving-the-Board-of-Directors-and-Welcomes-Michael-D-Goodman-as-New-Treasurer-and-Member-of-Board-of-Directors.html?f=22&fvtc=4&fvtv=28982BioNovelus Announces Marvin R Clark Leaving the Board of Directors, and Welcomes Michael D Goodman as New Treasurer and Member of Board of Directors2018-08-08T11:00:00Z<![CDATA[Phoenix, Aug. 08, 2018 (GLOBE NEWSWIRE) -- / BioNovelus, Inc. (OTC Pink: ONOV) today announced that Marvin R Clark has stepped down from the Company's board of directors, and as Treasurer for personal reasons, effective June 22, 2018.]]>https://www.globenewswire.com/news-release/2018/08/07/1548203/0/en/BIONOVELUS-CORRECTS-RELEASE-DATED-AUGUST-3-2018-AND-HAS-NOT-ENTERED-INTO-ANY-SETTLEMENT-AGREEMENT-WITH-L2-CAPITAL.html?f=22&fvtc=4&fvtv=28982BIONOVELUS CORRECTS RELEASE DATED AUGUST 3, 2018 AND HAS NOT ENTERED INTO ANY SETTLEMENT AGREEMENT WITH L2 CAPITAL2018-08-07T13:40:36Z<![CDATA[FOR IMMEDIATE CORRECTIVE RELEASE — Phoenix, Aug. 07, 2018 (GLOBE NEWSWIRE) -- — As previously announced, BioNovelus (ONOV) (the “Company”) did enter into a Claim Purchase Agreement on June 30, 2018 with L2 Capital, LLC (“L2”) to make payments toward certain past due debts purchased by L2 and that on July 18, 2018, L2 filed a complaint against the Company to collect on payment of its purchased claims totaling approximately $100,000. However, notwithstanding the previous release dated August 3, 2018, the parties have not entered into a settlement and mutual release agreement as of July 5, 2018 (the “Settlement Agreement”) whereby within seven (7) calendar days approval of the Settlement Agreement by the Court, the Company would issue shares of common stock (the “Shares”) to L2 in settlement of all outstanding claims at a forty percent (40%) discount to the lowest trade price of the Company’s common stock over the immediately preceding thirty (30) days.]]>https://www.globenewswire.com/news-release/2018/08/03/1547063/0/en/BIONOVELUS-ENTERS-INTO-SETTLEMENT-AND-MUTUAL-RELEASE-AGREEMENT-AND-RELATED-STIPULATED-JUDGMENT-WITH-L2-CAPITAL-LLC.html?f=22&fvtc=4&fvtv=28982BIONOVELUS ENTERS INTO SETTLEMENT AND MUTUAL RELEASE AGREEMENT AND RELATED STIPULATED JUDGMENT WITH L2 CAPITAL, LLC2018-08-03T15:55:15Z<![CDATA[FOR IMMEDIATE RELEASE —Phoenix, Aug. 03, 2018 (GLOBE NEWSWIRE) -- — BioNovelus (OTC Pink: ONOV) (the “Company”) entered into a Claim Purchase Agreement on June 30, 2018 with L2 Capital, LLC (“L2”) to make payments toward certain past due debts purchased by L2. On July 18, 2018, L2 filed a complaint against the Company to collect on payment of its purchased claims totaling approximately $100,000. On July 5, 2018, the parties entered into a settlement and mutual release agreement (the “Settlement Agreement”) whereby within seven (7) calendar days approval of the Settlement Agreement by the Court, the Company would issue shares of common stock (the “Shares”) to L2 in settlement of all outstanding claims at a forty percent (40%) discount to the lowest trade price of the Company’s common stock over the immediately preceding thirty (30) days. The shares will be issued as freely trading shares under Section 3(a)(10) of the Securities Act of 1933, as amended. The Company has retained counsel to answer and defend the lawsuit.]]>https://www.globenewswire.com/news-release/2018/05/15/1502164/0/en/BIONOVELUS-FIRST-QUARTER-REPORTS.html?f=22&fvtc=4&fvtv=28982BIONOVELUS' FIRST QUARTER REPORTS2018-05-15T00:45:07Z<![CDATA[FOR IMMEDIATE RELEASE — Phoenix, May 14, 2018 (GLOBE NEWSWIRE) -- / BioNovelus (OTC Pink: ONOV) has published today its first quarter of 2018 financial statements and report.]]>https://www.globenewswire.com/news-release/2018/04/26/1488077/0/en/BioNovelus-Receives-Organic-Certification-for-CR-10.html?f=22&fvtc=4&fvtv=28982BioNovelus Receives Organic Certification for CR-10®2018-04-26T12:00:00Z<![CDATA[FOR IMMEDIATE RELEASE — Phoenix, April 26, 2018 (GLOBE NEWSWIRE) -- — BioNovelus is proud to announce that its flagship product CR-10®, a non-toxic, organic fungicide has received the organic certification from Mayacert.]]>https://www.globenewswire.com/news-release/2018/03/02/1414070/0/en/BIONOVELUS-C-I-O-DEPARTURE.html?f=22&fvtc=4&fvtv=28982BIONOVELUS C.I.O.DEPARTURE2018-03-02T12:00:00Z<![CDATA[FOR IMMEDIATE RELEASE / Phoenix, March 02, 2018 (GLOBE NEWSWIRE) -- / BioNovelus, Inc. (ONOV), whose CR-10® Biofungicide is a non-toxic solution for safe and effective pre- and post-harvest applications, is announcing effective immediately, that Anthony Parkinson, Chief Information Officer, is no longer employed with BioNovelus. We wish him well in his new endeavor. Also, Mr. Parkinson has resigned from his board seat, effective immediately.]]>https://www.globenewswire.com/news-release/2017/11/14/1185672/0/en/BioNovelus-agrees-to-Co-Directorship-and-advisory-with-Meroe-Capital-Group-Ltd.html?f=22&fvtc=4&fvtv=28982BioNovelus agrees to Co-Directorship and advisory with Meroe Capital Group Ltd. 2017-11-14T11:00:00Z<![CDATA[FOR IMMEDIATE RELEASE — Phoenix, Nov. 14, 2017 (GLOBE NEWSWIRE) -- — BioNovelus (ONOV) has today announced the retention of New York-based Meroe Capital Group Ltd.]]>https://www.globenewswire.com/news-release/2017/10/18/1149141/0/en/Mission-of-BioNovelus-CR-10-Leading-to-Healthier-Crops-in-Central-America.html?f=22&fvtc=4&fvtv=28982"Mission" of BioNovelus' CR-10 Leading to Healthier Crops in Central America2017-10-18T11:30:00Z<![CDATA[FOR IMMEDIATE RELEASE — Phoenix, Oct. 18, 2017 (GLOBE NEWSWIRE) -- — An internally created promotional video is helping BioNovelus President and CEO Jean Ekobo spread the word about the company’s non-toxic, organic fungicide and the very strong early results that farmers who are using it are reporting.]]>https://www.globenewswire.com/news-release/2017/10/13/1145255/0/en/BIONOVELUS-EDUCATIONAL-SERIES-LEADING-TO-SALES.html?f=22&fvtc=4&fvtv=28982BIONOVELUS' EDUCATIONAL SERIES LEADING TO SALES2017-10-13T00:32:25Z<![CDATA[FOR IMMEDIATE RELEASE — Phoenix, Oct. 12, 2017 (GLOBE NEWSWIRE) -- / The “Introduction to Disruptive Agricultural Solutions” events that BioNovelus (OTC Pink: ONOV) began co-hosting in Guatemala in the summer are continuing with great success.]]>https://www.globenewswire.com/news-release/2017/10/04/1140951/0/en/BioNovelus-CR-10-Blooms-from-Innovation-to-Market.html?f=22&fvtc=4&fvtv=28982BioNovelus’ CR-10 Blooms from Innovation to Market2017-10-04T21:29:10Z<![CDATA[Phoenix, Oct. 04, 2017 (GLOBE NEWSWIRE) -- / FOR IMMEDIATE RELEASE — After months of trials conducted in partnership with several companies in the crop protection, post-harvest, and food security spaces, BioNovelus (ONOV) is delighted to announce the beginning of the commercialization of its eco-friendly, Biofungicide CR-10.]]>